Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H29NO |
Molecular Weight | 311.4611 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](O)C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=QIRAYNIFEOXSPW-PXNSSMCTSA-N
InChI=1S/C21H29NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,20,23H,5,16H2,1-4H3/t17-,20-/m0/s1
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
139 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DINORACETYLMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
184 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NORACYMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
188 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LEVOMETHADYL ACETATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5892 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DINORACETYLMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6056 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NORACYMETHADOL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2995 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15380290 |
80 mg 1 times / 2 days steady-state, oral dose: 80 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LEVOMETHADYL ACETATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mg/kg multiple, oral Studied dose Dose: 3 mg/kg Route: oral Route: multiple Dose: 3 mg/kg Sources: |
unhealthy, 23 - 57 years n = 6 Health Status: unhealthy Condition: heroin dependency Age Group: 23 - 57 years Sex: M+F Population Size: 6 Sources: |
Disc. AE: Cardiotoxicity... AEs leading to discontinuation/dose reduction: Cardiotoxicity (6 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiotoxicity | 6 patients Disc. AE |
3 mg/kg multiple, oral Studied dose Dose: 3 mg/kg Route: oral Route: multiple Dose: 3 mg/kg Sources: |
unhealthy, 23 - 57 years n = 6 Health Status: unhealthy Condition: heroin dependency Age Group: 23 - 57 years Sex: M+F Population Size: 6 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15104241/ Page: 7.0 |
minor | |||
yes | likely (co-administration study) Comment: the addition of drugs that induce this enzyme (such as rifampin, phenobarbital, and phenytoin) or inhibit this enzyme (such as ketoconazole, erythromycin, and saquinavir) could increase the levels of parent drug or its active metabolites in a patient that was previously at steady-state, and this could potentially precipitate serious arrhythmias, including torsade de pointes |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
14019-10-4
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY | |||
|
6441
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY | |||
|
DTXSID70161253
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY | |||
|
237005
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000089491
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY | |||
|
3041256
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY | |||
|
QZH7WR4VKJ
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY | |||
|
SUB14352MIG
Created by
admin on Fri Dec 15 15:44:13 GMT 2023 , Edited by admin on Fri Dec 15 15:44:13 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD